8 recruiting, 3 not yet recruiting, 2 active not recruiting. 8 Phase 1, 7 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Not yet recruiting 3, Active not recruiting 1 |
| Phase 2 | 7 | Recruiting 5, Active not recruiting 2 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Liping Dou: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia CLL-1-CD70 CAR-T Cell Injection - Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-11-30 | 2026-10-27 |
| BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma SL4903 Injection (BCMA/GPRC5D Dual-Target Autologous CAR-T Cell Injection) - Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Liping Dou | 20 | 2026-11-30 | 2026-11-10 |
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia SL1CC Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-10-01 | 2026-10-02 |
| CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) - Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T | Phase 1 | Recruiting | Liping Dou | 12 | 2026-09-01 | 2026-11-10 |
| Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF - R/R AML | Phase 2 | Active not recruiting | Liping Dou | 32 | 2026-07-30 | 2026-10-15 |
| Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim, Best Supportive Care (BSC) - Hematologic Diseases | Phase 2 | Recruiting | Liping Dou | 120 | 2026-06-01 | 2026-11-06 |
| In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms In vivo BCMA/GPRC5D Tandem Dual CAR-T cell - Plasma Cell Neoplasms | Early Phase 1 | Recruiting | Liping Dou | 18 | 2026-05-09 | 2026-10-02 |
| CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Recruiting | Liping Dou | 30 | 2026-04-01 | 2026-08-21 |
| Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-06-15 |
| CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Recruiting | Liping Dou | 20 | 2026-01-01 | 2026-05-14 |
| Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Liping Dou | 30 | 2026-01-01 | 2026-06-25 |
| A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Azacitidine (AZA) Days 1 - 5, Selinexor - Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | Active not recruiting | Liping Dou | 58 | 2025-05-01 | 2026-08-21 |
| Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL Blinatumomab Injection, Donor Lymphocyte Infusion (DLI) - ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Recruiting | Liping Dou | 60 | 2024-12-01 | 2026-07-01 |
Burkitt Lymphoma (3) · Leukemia, Myeloid, Acute (3) · Recurrence (3) · Cytokine Release Syndrome (2) · Lymphoma (2) · Neoplasm, Residual (2) · Anemia, Refractory, with Excess of Blasts (1) · Hematologic Diseases (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1)
Azacitidine (2) · Cytarabine (1) · Granulocyte Colony-Stimulating Factor (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · blinatumomab (1) · romiplostim (1) · selinexor (1)
China (13)
Li-Ping Dou, Dr. (1)